Characterization of Binding of an RGD Mimetic, [³H]-SC-52012, to Platelet GPIIb/IIIa.

Autor: Panzer-Knodle, S. G., Jacqmin, P., Page, J. D., Nicholson, N. S., Zablocki, J. A., Engleman, V. W., Feigen, L. P.

Publikováno v: Platelets; 1995, Vol. 6 Issue 5, p288-295, 8p

Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.

Autor: Carron CP; Departments of Discovery Pharmacology, Medicinal Chemistry and Oncology, Searle Research and Development, Monsanto Company, St Louis, Missouri, 63198, USA. chris.p.carron@monsanto.com, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA

Publikováno v: The Journal of endocrinology [J Endocrinol] 2000 Jun; Vol. 165 (3), pp. 587-98.

A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.

Autor: Engleman VW; Searle Corporation, St. Louis, Missouri 63167, USA., Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL

Publikováno v: The Journal of clinical investigation [J Clin Invest] 1997 May 01; Vol. 99 (9), pp. 2284-92.

SC-49992--a potent and specific inhibitor of platelet aggregation.

Autor: Nicholson NS; Department of Cardiovascular Diseases Research, Searle, Skokie, IL 60077., Panzer-Knodle SG, King LW, Taite BB, Keller BT, Tjoeng FS, Engleman VW, Giorgio TD, Feigen LP

Publikováno v: Thrombosis research [Thromb Res] 1994 Jun 01; Vol. 74 (5), pp. 523-35.